Table 3.
Univariate and multivariate analyses of distant metastasis-free survival.
| Characteristic | Primary cohort | PSM cohort | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate Cox regression analysis | Univariate analysis | Multivariate Cox regression analysis | |||||
| Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | |
| Age (years) | 0.697 (0.382–1.269) | 0.237 | 0.779 (0.378–1.605) | 0.498 | ||||
| Histological type | 3.337 (1.229–9.058) | 0.018* | 2.485 (0.913–6.765) | 0.075 | 4.658 (1.148–18.892) | 0.031* | 3.429 (0.841–13.969) | 0.086 |
| T stage# | 1.788 (1.436–2.227) | <0.001* | 1.197 (0.935–1.532) | 0.154 | 1.817 (1.435–2.300) | <0.001* | 1.242 (0.953–1.620) | 0.109 |
| N stage# | 2.014 (1.713–2.368) | <0.001* | 1.875 (1.565–2.246) | <0.001* | 1.945 (1.639–2.308) | <0.001* | 1.788 (1.477–2.165) | <0.001* |
| ER | 0.990 (0.650–1.507) | 0.962 | 0.990 (0.632–1.549) | 0.964 | ||||
| PR | 0.824 (0.560–1.212) | 0.324 | 0.780 (0.519–1.173) | 0.233 | ||||
| HER2 | 1.412 (0.958–2.080) | 0.081 | 1.120 (0.756–1.659) | 0.571 | 1.482 (0.986–2.228) | 0.058 | 1.098 (0.723–1.666) | 0.661 |
| Ki67 | 1.431 (0.931–2.199) | 0.102 | 1.554 (0.981–2.461) | 0.060 | 1.329 (0.835–2.115) | 0.230 | ||
| Molecular subtype | 1.002 (0.856–1.174) | 0.976 | 1.031 (0.873–1.217) | 0.722 | ||||
| SII | 1.721 (1.157–2.559) | 0.007* | 1.720 (1.156–2.561) | 0.008* | 1.635 (1.085–2.463) | 0.019* | 1.727 (1.144–2.607) | 0.009* |
A Cox proportional hazards model was used to conduct multivariate analyses. All variables were transformed into categorical variables. HRs were calculated for age (≥60 y vs. <60 y); histological type (invasive ductal carcinoma vs. others); T stage (T3-4 vs. T1-2); N stage (N2-3 vs. N0-1); ER (negative vs. positive); PR (negative vs. positive); HER2 (negative vs. positive); Ki67 (negative vs. positive); molecular subtype (others vs. luminal) and SII (high vs. low). We selected variables using the backward stepwise approach. The P-value threshold was 0.10 (P ≥ 0.10) for the removal of insignificant variables from the model.
P < 0.05: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; PSM, propensity score matching; SII, systemic immune-inflammation index.
According to the 7th edition of the UICC/AJCC staging system.